Literature DB >> 32215381

Recent advances of nanomedicines for liver cancer therapy.

Xiaoqin Chi1, Kun Liu2, Xiangjie Luo2, Zhenyu Yin3, Hongyu Lin2, Jinhao Gao2.   

Abstract

Liver cancer is one of the most prevalent cancers and the third leading cause of cancer-related deaths worldwide. Liver cancer is insensitive to chemotherapeutic drugs due to its intrinsic or acquired drug resistance and the inability of delivering sufficient drugs to tumors via current chemotherapy. The emergence of nanomedicines offers a potential solution for this challenge. Nanomedicines utilize nanoscale or nanostructured materials in medicines for particular medical purposes. In this review, we illustrate the recent developments of various nanomedicines for liver cancer by presenting selected examples at different stages. Diverse nanomaterials, varied targeting moieties, and specific strategies for controlled release of nanomedicines for liver cancer therapy are summarized. Multifunctional nanomedicines for liver cancer are also discussed. This comprehensive review is aimed at providing quick access for readers to the cutting-edge nanomedicines in liver cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32215381     DOI: 10.1039/c9tb02871d

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN: 2050-750X            Impact factor:   6.331


  2 in total

1.  A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma.

Authors:  Wenmin Hu; Yongmei Shi; Tongqin Han; Caiyun Liu; Xipeng Cao; Guangjun Shi; Wenjing Zhu
Journal:  Front Genet       Date:  2022-05-03       Impact factor: 4.772

2.  A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer.

Authors:  Zhiyuan Zhang; Tianhao Su; Yanjing Han; Zeran Yang; Jian Wei; Long Jin; Haining Fan
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.